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Introduction 
Peripheral neuropathy (PN) 
Peripheral neuropathy is a common neurologic disorder of diverse etiologies. Establishing the 
diagnosis may sometimes be difficult, and the highest likelihood predicting PN is the 
combination of multiple symptoms, multiple signs, and abnormal nerve conduction studies 
(NCS) (1). The patient’s symptoms and signs differ depending on which part of the peripheral 
nervous system is involved. In pure motor PN muscle weakness without sensory loss is the 
primary finding, and in pure sensory PN symptoms like numbness, tingling, or pain are 
prevailing. Upon neurologic examination evidence of both sensory and motor involvement are 
often revealed. In addition the patients may have symptoms and signs from the autonomic 
nervous system like orthostatic fall in blood pressure, heat intolerance, or bowel-, bladder-, or 
sexual dysfunction. No neuropathic symptoms, findings or tests are, however, consistently 
abnormal (2), and different composite scores with combinations of clinical findings and test 
abnormalities have been proposed for establishing a diagnosis (1,2).  
In PN all types of nerve fibers are usually involved, and the function of the fast 
conducting large-diameter nerve fibers can be evaluated through conventional neurologic 
examination by testing deep tendon reflexes and muscle strength. NCS, however, give a more 
accurate and objective measure of large-diameter nerve fiber function.  
In some patients selective pathological processes involving only small-diameter nerve 
fibers (myelinated Aδ- and unmyelinated C-fibers) sometimes occur (3,4). Small-fiber 
neuropathy is classified as a subtype of PN in which both sensory and autonomic nerve fibers 
may be involved (5,6). The patients typically have positive sensory symptoms like tingling, 
burning, prickling or shooting pain (5,6). Negative sensory symptoms like decreased or 
abolished ability to perceive cold, warmth, or noxious stimuli are less likely to be reported 
(7), and pure autonomic neuropathies are rare (6). Small-fiber neuropathy is reported in 
various diseases like diabetes mellitus, HIV infection, Fabry disease, alcohol abuse, and 
systemic amyloidosis, although most cases are idiopathic (3,5,6,8-10). These patients will 
have no neurologic deficits except impairment of pain and temperature sensation and/or 
autonomic disturbances, and the nerve conduction velocities will be normal unless larger 
nerve fibers are involved.  
The small-diameter myelinated Aδ- and unmyelinated C-fibers functions are most 
commonly investigated by quantitative sensory testing devices for determination of 
perception thresholds to warmth, cold, and pain (6). In addition, other tests like sympathetic 
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skin response, quantitative sudomotor axon reflex, microneurography, somatosensory-evoked 
cortical potentials, laser-evoked potentials, contact heat-evoked potentials, cutaneous silent 
period, and cardiovagal and adrenergic autonomic tests have been or are used in the 
investigation of small-fiber neuropathy (5,6). However, none of the tests are established as 
standard methods for testing small-diameter nerve fiber function.  
Until recently, no easily feasible test to evaluate the density of small-diameter nerve 
fibers existed. By immunostaining the neuropeptide protein gene product 9.5 (PGP 9.5) it 
became possible to visualize small-diameter nerve fibers by immunohistochemical techniques 
(11). Since the small-diameter nerve fibers traverse the skin perpendicular to the epidermis, 
the density of small-diameter intra-epidermal nerve fibers (IENF) can be quantitated in punch 
skin biopsies, and normative reference ranges for densities of these nerve fibers are available 
(12). This method has later been considered an objective and reproducible procedure for 
evaluation of small-diameter nerve fiber densities (12,13).  
 
Systemic lupus erythematosus (SLE)  
SLE is a chronic inflammatory autoimmune disease. It is characterized by a variety of clinical 
and immunological abnormalities, and the principal underlying immune disorder is an 
abnormal cellular and humoral immune response with excessive T-cell help, polyclonal B-cell 
activation, and the production of numerous auto-antibodies of diverse specificities (14). The 
autoantibodies may be directed against components of the cell nucleus of which antibodies 
against nucleosomes, double-stranded DNA (dsDNA) and histones are believed to be of 
pathogenetic significance (15-17). The type I interferon system has been proposed to have a 
central role in the pathogenesis of SLE, and it has been shown that necrotic and late apoptotic 
cells release material that in combination with IgG from SLE patients can induce production 
of interferon α in plasmacytoid dendritic cells generating autoimmune T and B cells (18-20).  
The clinical spectrum of the disease is wide, from an almost asymptomatic clinical 
presentation to a severe life-threatening disease affecting several internal organs. The 
prevalence varies in different reports from 36-68 cases per 100.000 persons with an incidence 
of approximately 3-5 per 100.000 persons (21-23).  A recent Scandinavian study reports better 
survival, less renal involvement and therefore a higher prevalence of the disease, and the 
median age at diagnosis in this study was 47 years (23). This may be due to a higher 
awareness among physicians and/or more aggressive treatment with better survival. The five 
and 10 year survival rates were 93% and 83% respectively in a recent Swedish study, and 
only the 10 year survival was reduced compared to age and sex matched healthy individuals 
  15  
(23). However, the mortality rate is about threefold higher in Blacks with SLE, and twofold 
higher in Asians compared to Caucasians (24). The incidence and prevalence of SLE is higher 
in women compared to men, and there is also a higher incidence in African-Americans 
compared to whites (3,25). The female to male ratio at onset before puberty is 2.0, peaks to 
8.0 in the forties and then declines to 2.3 after 60 years of age (26). These observations point 
to genetic, environmental, and hormonal factors as important players for the development of 
SLE.  
 The diagnosis of SLE is based on symptoms and clinical findings as well as on 
hematologic and biochemical abnormalities like detection of nuclear autoantibodies, anti-
phospolipid antibodies, or positive anti-phospholipid antibody dependent tests. The American 
Rheumatism Association (ARA), later the American College of Rheumatology (ACR), first 
published preliminary classification criteria for SLE in 1971 and revised them in 1982 and 
1997, when a positive LE cell preparation was replaced with abnormal serum levels of 
antiphospholipid antibodies and/or a positive test result for lupus anticoagulant (Table 1) 
(27,28). A patient is classified as having SLE if any four or more of the 11 criteria are present 
serially or simultaneously during any interval of observations. The classification criteria were 
developed primarily for research purposes, but are also useful for evaluating individual 
patients. 
 There has not been a universal agreement on evaluation of the disease activity in 
patients with SLE, and about 60 different indices have been proposed (29). A disease activity 
index is important for evaluating the response to treatment and in research for comparison 
between different groups of patients with SLE. The systemic lupus erythematosus disease 
activity index (SLEDAI) is a model based on clinicians’ global judgements of various clinical 
variables for describing activity in patients with SLE (30). SLEDAI is a validated instrument 
based on 24 variables from nine organ systems (30). The maximum score is 105, but few 
patients will have scores greater than 45. A flare or improvement of disease activity is 
proposed as an increase or decrease in SLEDAI of > 3, and complete remission as a SLEDAI 
of 0 (31). Organ damage caused by the disease is evaluated by a damage index defined by the 
systemic lupus international collaborating clinics (SLICC), as an irreversible change in an 
organ or system that has occurred since the onset of SLE and is present for at least six months 
(32). Twelve organ systems are scored, and the SLICC damage index increases with disease 
duration and is associated with mortality (33).  
 PN in SLE is reported to occur with a prevalence of 5 – 27% dependent on criteria 
applied and patient population studied, and is characterized by a length dependent mild 
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sensory or sensorimotor neuropathy (34-37). Usually, the neuropathic process is modestly 
progressive over time, but may fluctuate and is not necessarily irreversible (38).  Moreover, 
mono-neuropathies or multiple mono-neuropathies can sometimes occur on the basis of a 
vasculitic process or as part of a more generalized neuropathic process in the nervous system. 
  
Primary Sjögren´s syndrome (PSS)  
PSS is an autoimmune disease mainly affecting exocrine glands and is clinically characterized 
by symptomatic dryness of mucous membranes including the eyes (keratoconjuntivitis sicca) 
and oral cavity (xerostomia) (39). The histological hallmark is a focal infiltration of 
mononuclear lymphoid cells, predominantly T-cells with fewer B-cells and macrophages, in 
the exocrine glands replacing glandular epithelium (39). A large number of autoantibodies 
have been reported of which the non-organ specific autoantibodies anti-SSA (Ro) and anti-
SSB (La) are best characterized. Onset of the disease is usually insidious, and more than half 
of the patients develop extraglandular manifestations like myalgias, arthralgias, and 
involvement of the pulmonary-, and gastrointestinal system (40). General and unspecific 
phenomena like fatigue are also considered frequent. PSS is a worldwide disease and may 
occur in all ages with a peak incidence in the fourth and fifth decade of life and a female to 
male ratio of 9:1 (40). The prevalence is estimated not to exceed 0.6% (40,41). 
The diagnosis of PSS is, like for SLE, in clinical practice often based on a pragmatic 
use of symptoms, signs, laboratory, and histological features. For research purposes 
classification criteria have been published, but until recently several sets of diagnostic criteria 
existed resulting in non-comparable findings in different studies (42-45). In 2002 an 
international consensus group published revised classification criteria for primary- and 
secondary Sjögren’s syndrome (46). Having PSS according to this classification requires four 
of six criteria including positive lip biopsy and/or positive antibodies to anti-SSA and/or anti-
SSB (Table 2) (46). The diagnosis can also be achived if three of the four objective criteria 
are present. No validated disease activity index exists for PSS.   
The most common abnormality in the peripheral nerves in patients with PSS has 
reportedly been a symmetric sensorimotor PN followed by a symmetric pure sensory PN 
(47,48). However, to our knowledge no longitudinal or cross sectional studies have been 
published in support of this. Also, the reported prevalence of neurologic manifestations vary 
between published studies most likely due to selection bias and not at least because of the 
changing diagnostic criteria for PSS during the last few years.  
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In PSS a T-lymphocyte infiltration in the dorsal root ganglia affecting sensory neurons 
have been reported as part of a ganglionitis (49). This condition is probably an infrequent 
phenomenon and is clinically characterized by gait and limb ataxia and also hyperalgesic 
symptoms at proximal sites. The symptoms in these patients do not follow the typical dying-
back process of axonal neuropathies with symptoms starting in the distal part of the limbs but 
involve both proximal and distal areas of the body. In healthy subjects the IENF densities are 
reported to be higher in the proximal thigh compared to the distal leg generating a proximal-
distal gradient (12). However, in patients with ganglionopathies no such gradients are 
reported (50). In these patients the inflammatory process in the ganglia results in degeneration 
of the sensory neurons, which is reflected in a non-length distribution of symptoms, abnormal 
NCS in both upper and lower limbs, and also by reduced densities of IENF in both proximal 
and distal sites of the limbs resulting in no proximal-distal gradients in IENF densities (50).  
 
Rheumatoid arthritis (RA)  
RA is a chronic, inflammatory, symmetrical, destructive arthritis primarily involving the 
metacarpophalangeal-, proximal interphalangeal-, wrist- and metatarsophalangeal joints. 
Extra-articular manifestations usually reflect severe disease often accompanied with high 
levels of rheumatoid factor and signs of high inflammatory activity (51). The prevalence in 
most populations is 0.5 – 1.0% (52-54). The incidence is, however, declining, and the 
reported incidence is today 25-50/100,000 with a 4:1 ratio of women to men in the 35-44 age 
group compared to 1:1 in the 75-84 age group (54-56). The declining incidence might 
implicate specific environmental factors among which temporal changes in the incidence of 
infectious agents and exposure to the contraceptive pill have been proposed (55,57).  
Multiple cells contribute to the chronic inflammation, but synovial fibroblasts seem to 
be the key cells in the propagation of RA (58). The synovial fibroblasts secrete a number of 
proangiogenic factors and proinflammatory factors that activate T-cells inducing T-cell 
proliferation and production of cytokines (58,59). The inflammatory process stimulates 
pannus formation, bone-, and cartilage damage (58,59). 
Compression neuropathies have been considered common in RA (60), although a 
controlled study disputed this by disclosing more carpal tunnel syndromes in healthy subjects 
compared with patients with RA (61). A mild distal symmetric sensory neuropathy is 
considered a late complication to the disease. Rarely, mono- and multiple mono-neuropathies 
are reported in association with the very serious condition of rheumatoid vasculitis (60). 
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Aims of the study 
 
1) To establish normative values for IENF densities based on findings in healthy subjects 
and to test the intra- and interobserver variation for the method. 
2) To investigate the prevalence of small-diameter nerve fiber neuropathy in patients 
with chronic inflammatory diseases with main focus on SLE. 
3) To investigate if small-diameter nerve fiber neuropathy is an isolated phenomenon in 
patients with SLE and PSS or if it is part of a more generalized and diffuse neuropathy 
involving both small- and large-diameter nerve fibers. 
4) To investigate the spectrum of peripheral neuropathy in patients with PSS fulfilling 
the revised international diagnostic criteria. 
5) To investigate if the involvement of small-diameter nerve fibers varies between 
different chronic inflammatory diseases like SLE, PSS and RA. 
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Subjects and methods 
Patients and healthy subjects 
The patients in these studies were recruited in the following manner: In paper I the patients 
were recruited from the outpatient clinic of the Department of Rheumatology, University 
Hospital of North Norway, Tromsø. In paper III – V from the Department of Internal 
Medicine, Stavanger University Hospital. In paper V the patients with RA were recruited 
from the outpatient clinic of the Department of Rheumatology, Haukeland University 
Hospital. The University Hospital of North Norway provides local hospital services to about 
150,000 inhabitants of Troms county, and central and regional hospital services to the 
counties of Troms, Finnmark and part of Nordland, with at total of 450,000 inhabitants. Most 
SLE patients are treated on a local hospital basis. Stavanger University Hospital provides 
local hospital services to about 290,000 inhabitants of Rogaland county, and Haukeland 
University Hospital to about 370,000 inhabitants of Hordaland county. In the southern part of 
Rogaland county (290,000 inhabitants) all patients with systemic autoimmune diseases are 
allocated to Stavanger University Hospital, and the studies on SLE and PSS originating from 
this area may therefore be considered close to population based. 
In paper I, 15 consecutive and non-selected patients with SLE fulfilling the revised 
ACR criteria for SLE (28) were recruited. The age- and sex matched controls were friends 
and neighbors of the hospital staff. 
In paper III – V, all medical records of in- and outpatients at Stavanger University 
Hospital with a diagnosis of SLE from 1980 through 2003 were reviewed. We identified 73 
patients with SLE, all Caucasian, fulfilling the revised ACR criteria for SLE (28), and 60 
patients gave their consent to participate. For PSS all medical records from 1980 through 
2004 were reviewed, and in addition descriptions of positive lip biopsies diagnosed in the 
hospital’s Department of Pathology were retrieved and the patients were thereafter screened 
for PSS. We identified 67 patients with PSS fulfilling the new revised international diagnostic 
criteria for PSS (46), and 62 patients gave their consent to participate. In addition an 
unselected group of 52 consecutive patients with RA fulfilling the ACR criteria (62) were 
recruited. All patients were reexamined whenever in doubt for fulfilling the diagnostic 
criteria, and only patients and healthy subjects giving informed consent were included. 
The 106 healthy subjects in paper II were recruited from friends, hospital staff, and 
friends of the former. Healthy subjects were asked about their use of drugs and screened for 
concomitant conditions possibly associated with PN such as diabetes mellitus, thyroid disease, 
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and alcohol abuse.  
 
Clinical examination 
All patients with SLE or PSS were subjected to a standardized clinical and neurological 
examination by an experienced internist and a neurologist, respectively, and the patients were 
classified as having neuropathy or not according to the neurologist’s standards of 
conventional neurologic examination. In Tromsø and also in Bergen, only one experienced 
rheumatologist performed the general clinical examination. 
 
Quantitative scoring systems for neurological symptoms and signs 
Quantitative scoring systems were used to score neuropathic symptoms and signs and in 
combination with other tests like NCS to judge the presence and severity of neuropathy in any 
given patient (63).  
 
Symptoms. Neuropathy Symptom and Change score (NSC) is a standardized questionnaire for 
neuropathic symptoms based on an interview by a neurologist (2,7,64). The NSC scores are 
derived from answers to 38 questions (muscle weakness, sensation and autonomic symptoms). 
Number equals number of symptoms and the severity equals number of symptoms multiplied 
by severity (1 = mild, 2 = moderate, and 3 = severe). The questions are also subdivided by 
anatomical site, by positive and negative sensory symptoms, and by large-diameter and small-
diameter nerve fiber sensory symptoms. In the SLE study only items for sensory symptoms 
were recorded according to the hypothesis of involvement of small-diameter nerve fibers as 
the main interest. Subjects without neuropathy will typically have a score of 0.  
 
Signs. Neuropathy Impairment Score (NIS) is a graded evaluation of neuropathic impairment 
obtained by a standardized neurologic examination and scored into four subsets: cranial nerve 
function, muscle weakness, reflexes and sensory deficits (2,63,64). Age, sex and physical 
fitness are also taken into account by the examiner. Typically, persons without neuropathy 
will have a score of 0, and a score > 2 is regarded as abnormal (2). 
 
Nerve conduction studies (NCS) 
Patients with SLE or PSS were examined. Surface stimulating and recording electrodes under 
standard temperature conditions were used and the results were corrected for patients’ height. 
The amplitude, velocity, distal latency and the F-response of motor fibers of the median, 
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ulnar, peroneal, and tibial nerves were recorded bilaterally, as well as the amplitude, and the 
velocity of sensory fibers of the median, ulnar and sural nerves. In Stavanger we recruited 82 
healthy subjects for establishing normative values for sensory data (mean + 1.96 SD). For 
motor NCS the manufacturer´s (Dantec Keypoint apparatus, Dantec Medical A/S, Skovlunde, 
Denmark) recommendations based on data from the Department of Clinical Neurophysiology, 
University Hospital, Uppsala, Sweden, were used. Abnormal NCS in two or more nerves were 
defined as the neurophysiological criterion for PN (65). At the University Hospital of 
Northern Norway, Tromsø (Paper I) the neurophysiological laboratory’s reference values 
were used for both sensory and motor nerves. 
 
Skin punch biopsies 
The skin biopsies were performed with a 3 mm disposable circular punch needle (Biopsy 
Punch, Stiefel Laboratories Ltd., Sligo Ireland) with a sterile technique after local 
anesthetizing with 2% lidocaine with adrenaline. Two biopsies were obtained from each 
person on the same leg in the same procedure approximately 10 cm above the lateral 
malleolus. The biopsies were taken from the right leg. The left leg was used if the skin on the 
right leg was inflamed or had scars. In patients with PSS and in a group of healthy subjects 
two biopsies were also obtained from the proximo-lateral part of the thigh about 20 cm 
distally from spina ilica anterior with the same technique as from the leg.  
The specimens were immediately fixed in 2% paraformaldehyde, lysine and periodate 
fixative at + 4°C. After 12-24 hours, the biopsies were rinsed in 0.1M Sørensen`s buffer and 
placed in cryoprotectant solution of 20% glycerol/ Sørensen`s buffer at + 4°C overnight. The 
next day 50 μm sections were produced in a Leica CM 3050 cryostat. Alternatively, mounted 
specimens were frozen in liquid nitrogen and stored in - 70°C freezer for later sectioning. 
After cutting, the sections were stored in antifreeze solutions (mixture of glycerol (30%) and 
ethylene glycol (30%) in Sørensen`s buffer) for up to one week at - 20°C before used for 
immunostaining.  
Sections were rinsed twice, 10 minutes each time, in 0.25M TRIS-HCL buffer 
(TBS)/1.5% NaCl, pH 7.4 in microtiter wells. The sections were transferred into 0.25% 
potassium permanganate for 15 minutes, and subsequently rinsed for 10 minutes in TBS. 
Bleaching in 5.0% oxalic acid for 5 minutes was followed by two rinses in TBS. 
For protein blocking, sections were then transferred into 1.0% Triton-X 100 and 4% 
normal goat serum (NGS) (Dako, Denmark) in 0.25 TBS with 0.5% milk powder for 4 hours 
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at room temperature on a shaker table. The sections were then incubated at + 4°C overnight in 
wells containing 0.1% rabbit polyclonal antibodies to human PGP 9.5 (Chemicon 
International, Temecula, CA, USA) suspended in 0.5% Triton-X and 2% NGS in TBS with 
0.5% milk. Subsequently the sections were rinsed in TBS and incubated for 1h in 1% 
secondary antibody (goat anti-rabbit IgG, Dako, Denmark) in 0.5% Triton-X 100/2% NGS in 
0.25M TBS. Afterwards, the sections were rinsed in 0.25M TBS and endogenous peroxidase 
blocked with 1% H2O2 in 40% methanol/phosphate buffered saline (PBS), and then rinsed in 
0.01M PBS. They were subsequently placed in avidin-biotin complex solution (1% 
streptavidin (Dako) in 0.01M PBS, and 1% biotinylated peroxidase (Dako)) for 1 hour at 
room temperature followed by rinsing in PBS. Thereafter the sections were transferred into 
Vector SG peroxidase substrate (Vector SG substrate kit for perocidase, Vector Labs, 
Burlingame, USA) and incubated for 2-10 minutes for the chromogen development reaction 
and rinsed again in PBS before mounting on slides in 0.01% Triton-X 100 in 0.01M PBS. 
After drying, the sections were counterstained with eosin and coverslipped with Histokit 
(Assistant, Sondheim, Germany). 
The number of separate IENF in at least three sections from each biopsy was counted 
and the total length of epidermis was measured using the NIH Image 1.61 morphometry 
program (http:/rsb.info.nih.gov/nih-image/). The number of nerve fibers per mm was then 
reported as the mean of counts in six sections, three from each of the two biopsies. Only the 
single fibers and not the branches from the same IENF were counted. One single observer 
assessed all the biopsies, except in the interobserver part of the study (Paper II).  
 
Blood and urinary samples 
Healthy subjects were screened for cobalamin deficiency, and thyroid disease. Patients with 
SLE, PSS, and RA were screened with hematological and biochemical tests (plasma glucose, 
cobalamin, folic acid, and thyroid function tests), antinuclear antibodies (ANA), and the 
complement factors C3 and C4. In addition anti-dsDNA antibodies, anti-SSA - and anti-SSB 
antibodies were tested for in patients with SLE or PSS respectively. Conventional urinary 
analyses with dip-stick and microscopy were also performed. 
 
Disease activity instruments 
In patients with SLE, the disease activity was evaluated using the SLEDAI (30). The 
theoretically possible range is 0 – 105, but most patients have an index of less than 15 and 
very few patients an index greater than 45. The index is generated from disease activity 
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manifestations in nine different organ systems as well as presence or absence of selected 
immune parameters. DAS28 was used in patients with RA as disease activity index (66) and a 
score > 5.1 was defined as high disease activity (66). No validated disease activity index 
exists in PSS. 
 
Statistics 
Variables normally distributed were subjected to parametric statistics. Simple or multiple 
regression analysis were used to test associations between normally distributed quantitative 
variables. Unpaired t-tests (2-tailed) or analysis of variance (ANOVA) were applied when 
testing for two or more groups of quantitative data. To allow for multiple testing, the 
Bonferroni corrected method was applied for three or more numbers of comparisons. Non-
parametric statistics were applied for variables not normally distributed. The Spearman rank 
correlation test was used to test associations between such data. When appropriate, results are 
reported as mean + SD as well as median and range. 
To assess the reliability of IENF counting in skin punch biopsies, we estimated the 
intra- and interobserver agreements. The intra- and interobserver variability was estimated by 
calculating the arithmetric mean and the absolute differences between repeated measurements 
of the same biopsy. Agreement plots according to Bland and Altman were constructed (67). 
By this method any systematic differences between observers, or by intraobserver readings of 
IENF will result in the mean of the differences being significantly different from zero. The 
wider the scatter between the points in the direction of the Y-axis, the worse will be the 
agreement. We will expect 95% of the difference between paired counting’s to lie within + 2 
SD or more precisely + 1.96 SD of the mean, which is defined as the limit of agreement (67). 
Providing the differences are acceptable in clinical practice, the intra- and interobserver 
agreements are accepted.  
The statistical analysis was performed using the StatView packages. 
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Summary of results 
Paper I 
Small nerve fiber involvement in systemic lupus erythematosus 
In this study we investigated fifteen consecutive and unselected patients with SLE and 15 age- 
and sex-matched controls to evaluate the IENF densities in skin punch biopsies from the distal 
part of the leg about 10 cm proximal to the lateral malleolus. The small-diameter nerve fibers 
were visualized using immunostaining against PGP 9.5. The IENF density was 8.0 + 1.5/mm 
(range 5.0 - 9.9) in SLE as compared to 12.2 + 3.8/mm (range 6.8 – 18.6) in healthy controls, 
P = 0.0006.  
In conclusion, the IENF density was reduced in patients with SLE compared with age- 
and sex-matched controls. 
 
Paper II 
The effect of age and gender on epidermal nerve fiber density 
This is the first study to establish normative values for IENF densities in healthy Norwegian 
subjects. One hundred and six healthy volunteers were recruited; mean age 49.0 + 19.6 years 
(range 16.0 – 92.0). Two skin punch biopsies, 3 mm in diameter, were taken from the distal 
part of the leg about 10 cm proximal for the lateral malleolus and about one cm apart. The 
IENF were visualized using immunostaining against PGP 9.5. The mean IENF density was 
12.4 + 4.6 fibers/mm. Both increasing age and male gender were independently associated 
with decreasing IENF density. According to Bland and Altman plots (67) the mean difference 
in IENF densities by intraobserver analysis was 0.2  + 1.2 fibers/mm, and the mean difference 
by interobserver analysis was 0.4 + 1.5 fibers/mm, which were considered as acceptable in 
clinical practice.  
Conclusion: The skin punch biopsy technique is easy to perform and the reliability of 
the method is good. Normal means and ranges for the IENF densities in a reference 
population have been established. The IENF densities are reduced with increasing age and 
also with male gender. 
 
Paper III 
Small-diameter nerve fiber neuropathy in systemic lupus erythematosus 
In this study we investigated the involvement of small-diameter nerve fibers in 60 unselected 
patients fulfilling the revised ACR criteria for classification of SLE (28), 51 women and nine 
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men, mean age 43.2 + 13.5 years. 
The mean IENF density was 7.5 + 3.8 fibers/mm, and the densities were below the 
lower reference limit in eight patients (13%). Six of these patients (10%) had normal NCS and 
had no PN according to the clinical judgement by the neurologist. These patients were thus 
classified as having a pure small-diameter nerve fiber neuropathy. Four patients (7%) were 
considered to have PN by the clinical judgement of the neurologist, and 13 patients (22%) had 
abnormal NCS.  
The main conclusion from this study is that a certain proportion of patients with SLE, 
has an isolated small-diameter nerve fiber neuropathy, leaving larger nerve fibers unaffected. 
. 
Paper IV 
Intraepidermal nerve fiber densities in chronic inflammatory autoimmune diseases 
This is the first study comparing small-diameter IENF densities in three different groups of 
patients with chronic inflammatory autoimmune diseases SLE, PSS, RA and healthy subjects. 
Sixty patients with SLE (mean age 43.2 + 13.5 years), 61 patients with PSS (mean age 57.1 + 
14.6 years), and 52 patients with RA (mean age 57.4 + 12.3 years) were examined. The IENF 
densities in skin punch biopsies from the distal leg about 10 cm proximal to the lateral 
malleolus were 7.5 + 3.8 fibers/mm in SLE, 8.9 + 4.0 in PSS, 10.9 + 5.4 in RA and 12.4 ± 4.6 
in healthy subjects. The densities were significantly less in SLE compared with RA and also 
with healthy subjects, and in PSS compared with healthy subjects.  
These findings demonstrate that the involvement of small-diameter nerve fibers differs 
between different systemic autoimmune diseases probably reflecting differences in 
pathophysiology and organ affinity of the individual diseases. 
 
Paper V 
Peripheral neuropathy in primary Sjögren´s syndrome – a population based study 
This study is the first to evaluate the prevalence of neuropathy including small-diameter nerve 
fiber involvement in an unselected cohort of patients with PSS applying the revised 
international criteria (46). Sixty-two unselected patients, mean age 57.1 + 14.6 years were 
examined, 55 women and seven men. Seventeen patients (27%) were considered to have PN 
by an experienced neurologist. Thirty-four patients (55%) had abnormal NCS indicative of 
motor neuropathy in 19 patients (31%), sensory neuropathy in eight (13%), and sensorimotor 
neuropathy in seven patients (11%). Eight patients (13%) had concurrent PN at clinical 
examination and according to NCS. The mean IENF density in the leg was 9.2 + 3.8 
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fibers/mm as compared with 9.6 + 3.1 fibers/mm in the thigh, P = 0.37.  
In conclusion, PN is a frequent finding in PSS. A majority of these patients with PN 
have findings indicative of a subclinical demyelinating motor neuropathy on NCS mainly 
reflected as increased F-wave latencies. Only two patients had IENF densities below lower 
reference limit with normal NCS and normal neurologic examination reflecting that a pure 
small-diameter nerve fiber neuropathy is infrequent in PSS.  
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General discussion 
In paper I we showed that the densities of IENF in patients with SLE were reduced compared 
with age- and sex-matched controls and hypothesized that these findings may reflect the 
prevalent neuropathic symptoms and impaired warmth sense observed in these patients with 
otherwise normal NCS (68,69). The cohort was a non-selected small group of patients with 
SLE, and we revealed no association between IENF densities and variables like disease 
activity, disease duration, age, drug treatment or laboratory values. Only two patients had 
abnormal NCS, but the IENF densities in these two patients were not different from the 
others.  
 In paper II we investigated the IENF densities in healthy subjects to establish 
normative values from our own laboratory and define morphological criteria for small-
diameter nerve fiber neuropathy. While others had failed to demonstrate an association 
between IENF densities and age and gender (12), we found that the IENF densities were 
reduced with increasing age and with male gender also. This is a logic finding as most 
neurologic and neurophysiological variables display an age-dependent association (70-72). 
The explanation for the lower IENF density in males is, however, more speculative. Females 
have greater sensitivity for small temperature changes and lower heat pain threshold 
compared with males in most parts of the body, and these modalities are conveyed through 
small-diameter nerve fibers (73). Other explanations like higher consumption of alcohol, 
exposure to more occupational chemicals, and more wear and tear with repetitive physical 
trauma amongst men are other possibilities.  
 To evaluate the intra- and interobserver variability of the method we constructed 
agreement plots (Altman plot) (67). In the medical literature the agreement between two 
methods is often expressed as correlation coefficients. Such use of correlation is, however, 
misleading because a high correlation coefficient does not imply that the two measurements 
agree. Correlation should be confined to test possible associations between two continuous 
variables. We found the intra- and interobserver variability of the method to be acceptable in 
clinical practice.  
 We revealed a large variability in IENF densities between different sections from the 
same punch biopsy. The intraobserver variability decreased in one study from 13.5 + 12.6% 
to 6.4 + 7.9% counting four sections as opposed to two sections (13). The variability of IENF 
densities based on counting of three sections from one punch biopsy in the distal part of the 
leg was 44.9 fibers2/mm2 in the study by McArthur et.al (12). The variability was even higher 
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in the thigh, 108.2 fibers2/mm2, and the physiological proximal-distal gradient reported by 
these authors could therefore be due to the methodology used with three sections counted in 
one biopsy only (12). In contrast to others we count at least three sections in each of two 
biopsies taken about one cm apart from the same anatomical area for IENF density estimation, 
and calculate the mean of IENF/mm from at least six sections. The variability in the distal part 
of the leg was in our study 21.2 fibers2/mm2 (not published). We therefore strongly 
recommend the use of two biopsies from the same anatomical area and to count at least three 
sections from each biopsy to reduce the variability of the method. We defined the 
morphological criterion for small-diameter nerve fiber neuropathy as below the mean 
IENF/mm - 1.96 SD (< 3.4 fibers/mm). 
 In paper III we confirmed the findings of reduced IENF densities in an unselected 
cohort of SLE patients compared with healthy subjects. In six (10%) patients the IENF 
densities were below the lower limit although both the NCS and clinical examinations were 
normal. In addition 11 patients (18%) had an abnormal NCS, which is in accordance with 
previous reports (34-37). However, only four patients were classified as having PN by the 
experienced. IENF densities below lower reference limit without abnormalities at NCS or at 
the clinical examination point to a selective process affecting small-diameter nerve fibers in 
some patients with SLE. This occurs in spite of low disease activity. Potential pathogenetic 
mechanisms could be immunoglobulin deposition on neural surfaces or a low-grade 
inflammation of small blood vessels with an activated endothelium and the triggering of 
apoptotic signals and subsequent degeneration of the small-diameter nerve fibers (74-76). 
These observations point to different pathogenetic mechanisms being operative in small- and 
large-diameter nerve fibers, respectively, and indicate that small-diameter nerve fiber 
involvement may be an early phenomenon in the disease development. 
 In paper IV we compared the IENF densities in three different patient groups, SLE, 
PSS, and RA. Although these diseases have several similarities, the pathogenesis and also 
clinical manifestations differ between the disease entities. We found that the IENF densities 
were significantly lower in patients with SLE compared with RA, but there were no 
significantly differences between SLE and PSS or PSS and RA. However, the IENF densities 
were significantly less in SLE and PSS compared with healthy subjects, but no such 
difference was observed between RA and healthy subjects. Although not significant, there 
were differences in IENF densities between the groups of patients (Figure 1), and with a 
larger number of patients in each group this differences may have become significant. 
 RA is characterized by predominantly mono-organ involvement, SLE with systemic or 
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multi-organ involvement, and PSS somewhat in-between. In SLE the small-diameter nerve 
fibers may be a vulnerable target for a general immune activation, reflecting the systemic 
nature of the disease, or with a specific immune response targeting the nerve fibers. In 
patients with RA the small-diameter nerve fibers are not attacked due to the mainly joint 
involvement of the disease. In PSS, which has some characteristics of systemic as well as 
focal manifestations, the involvement of the small-diameter nerve fibers is somewhat in 
between the two other diseases. 
 In paper V we investigated the spectrum of PN including small-diameter nerve fiber 
neuropathy in an unselected cohort of patients fulfilling the new revised international 
diagnostic criteria for PSS (46). As far as we know this is the first study on neurologic 
features in a well-characterized group of unselected patients. We found an abnormal NCS in 
34 patients (55%). This consisted of motor neuropathy in 19 patients (31%), sensory in eight 
patients (13 %), and sensorimotor in seven patients (11%). Fifteen out of the 19 patients 
classified as having motor neuropathy at NCS had an abnormal F-wave latency in > 2 nerves 
as the only abnormality. The nerve conduction velocities between knee and ankle were 
significantly lower in patients with prolonged versus normal F-wave latency. Notably, the 
increased F-wave latencies were bilateral in all 15 patients, and for both groups of patients the 
conduction velocities were within the reference range. However, the more pronounced 
abnormalities in F-wave latency versus distal conduction velocity could theoretically be 
indicative of a more proximal than distal involvement, but none of the patients had a history, 
symptoms, or clinical findings of vertebral disc hernias. The F-wave latency is the single most 
sensitive neurophysiological parameter for detection of generalized motor nerve abnormalities 
(77,78). The long distance measured in the F-wave registration procedure improves the 
detection of minute abnormalities. In addition, the F-wave latency reference range is narrower 
than the conduction velocity reference range in the distal part of the nerve. In patients with 
SLE only four patients (7%) had reduced F-wave latencies indicating that the observations in 
patients with PSS are not accidental Although motor amplitudes were consistently lower in 
patients with increased F-wave latencies, these differences were nonsignificant, indicating 
that the prevailing neuropathic process is mainly demyelinating. However, the possibility of 
slight axonal involvement cannot be excluded. These observations contrast previous reports 
claiming that a symmetric sensorimotor PN followed by a symmetric pure sensory PN are 
most prevalent in patients with PSS (47,48). However, previous reports on this issue are 
hampered by selection bias due to changing diagnostic criteria and highly selected patient 
cohorts.  
  30  
 Seventeen patients (27%) achieved a diagnosis of neuropathy following clinical 
examination. The mean IENF density was 9.2/mm + 3.8 in the leg as compared with 9.6/mm 
+ 3.1 in the thigh, P = 0.37, and the IENF densities in the leg were significantly lower than in 
healthy subjects. In contrast to patients with SLE, only two patients had IENF densities below 
normative values combined with normal NCS and clinical examination. 
 The prevalence of PN was 13% based on a combination of findings on clinical 
examination and NCS. 
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 Figure 1 
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Conclusions 
By immunostaining the neuropeptide PGP 9.5 in punch skin biopsies, the small-diameter 
nerve fibers were visualized, quantitated, and normative values in a Norwegian population 
established. The intra- and interobserver variability were considered to be acceptable in 
clinical practice. Our studies demonstrate that the IENF densities are inversely associated with 
age, and men have lower densities than women. The variability of IENF densities between 
sections from the same biopsy is large, a finding with implications for the necessary numbers 
of sections counted and also for numbers of biopsies taken from each anatomical area.  
 Ten percent of the patients with SLE have a pure small-diameter nerve fiber 
neuropathy reflected by IENF densities below normative values, normal NCS, and normal 
neurological examination. Small-diameter nerve fiber loss is not associated with disease 
activity, autoantibodies, or medication, and the small-diameter nerve fibers are probably a 
target for the general immunological abnormalities taking place in these patients. 
 The IENF densities differ between autoimmune diseases like SLE, PSS, and RA. The 
densities are significantly less in patients with SLE compared to PSS and healthy subjects and 
in PSS compared to healthy subjects. Patients with RA have the same IENF densities as 
healthy subjects. These findings are indicative of different pathophysiology and organ affinity 
of the individual diseases. 
 Twenty-seven percent of the patients with PSS have PN as evaluated by an 
experienced neurologist. Fifty-five percent of patients with PSS have an abnormal NCS 
mainly reflecting motor neuropathy (31%) with increased F-wave latency, sensory neuropathy 
(13%), and sensorimotor neuropathy (11%). The group of PSS patients with abnormally 
increased F-wave latencies had significantly reduced conduction velocities compared with 
patients with normal F-wave latencies. The amplitudes were, however, not significantly 
reduced pointing to a demyelinating PN. Based on the combination of clinical examination 
and NCS the prevalence of PN was 13%. The IENF densities were reduced compared to 
healthy subjects on a group basis, but this was as part of a general neuropathic process 
affecting both small- and large-diameter nerve fibers. There were no gradient between IENF 
densities in the proximal thigh and distal leg probably reflecting normal IENF density 
distribution and not a general ganglionopathy in these patients.  
 The prevalence of small-diameter nerve fiber involvement differs between chronic 
systemic autoimmune diseases. In SLE the small-diameter nerve fibers are probably attacked 
early in the disease, which is reflected in a pure small-diameter nerve fiber neuropathy in 
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some of these patients. In PSS the small-diameter nerve fiber densities are reduced as part of a 
more general neuropathy, and in RA no significant reduction in small-diameter nerve fibers 
compared with healthy subjects could be detected. The pathogenesis is still largely unknown 
and should be explored in future studies.
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Table 1 
Classification criteria for SLE (28) 
 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences,  
 tending to spare the nasolabial folds.    
2. Discoid rash Erythematous raised patches with adherent keratotic scaling  
 and follicular plugging; atrophic scarring may occur in older    
 lesions. 
3. Photosensitivity  Skin rash as a result of unusual reaction to sunlight, by  
 patient’s history or physician’s observation. 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless,  
 observed by a physician. 
5. Arthritis  Nonerosive arthritis involving two or more peripheral joints,  
 characterized by tenderness, swelling or effusion. 
6. Serositis a) Pleuritis – convincing history of pleuritic pain or rub  
 heard by a physician or evidence of pleural effusion 
 or 
 b) Pericarditis – documented by ECG or rub or evidence of  
 pericardial effusion. 
7. Renal disorder a) Persistent proteinuria greater than 0.5 g per day or greater 
 than 3+ if quantitation not performed 
 or 
 b) Cellular casts – may be red cell, hemoglobin, granular, 
 tubular or mixed. 
8. Neurologic disorder a) Seizures – in the absence of offending drugs or known  
 metabolic derangements; eg uremia, ketoacidosis, or 
 electrolyte imbalance. 
 or 
 b) Psychosis – in the absence of offending drugs or known 
  metabolic derangements; eg uremia, ketoacidosis, or  
 electrolyte imbalance. 
9. Hematologic disorder a) Hemolytic anemia – with reticulocytosis 
 or 
 b) Leukopenia – less than 4000/mm3 total on two or more  
 occasions 
 or 
 c) Lymphopenia – less than 1500/mm3 on two or more 
 occasions. 
 or 
 d) Thrombocytopenia – less than 100 000/ mm3 in the 
 absence of offending drugs. 
10. Immunologic disorder a) Anti-DNA: antibody to native DNA in abnormal titer 
 or 
 b) Anti-SM: presence of antibody to Sm nuclear antigen 
 or 
 c) Positive finding of antiphospholipid antibodies based on: 
1) An abnormal serum level of IgG or IgM anticardiolipin  
  antibodies 
 or 
2) A positive test for lupus anticoagulant using a standard  
  method 
 or 
3) A false-positive serologic test for syphilis known to be 
  positive for at least 6 months and confirmed by Treponema 
  pallidum immobilization or fluorescent treponemal antibody 
  absorption test. 
11. Antinuclear antibody An abnormal titer of antinuclear antibody by 
 immunofluorescence or an equivalent assay at any point in  
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 time and in the absence of drugs known to be associated  
 with “drug induced lupus syndrome”. 
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Table 2  
Revised international classification criteria for 
Sjögren´s syndrome (46) 
 
I.  Ocular symptoms: a positive response to at least one of the following questions: 
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day? 
 
II.  Oral symptoms: a positive response to at least one of the following questions: 
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrently or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
 
III.  Ocular signs – that is, objective evidence of ocular involvement defined as a positive 
       result for at least one of the following two tests: 
1. Schirmer´s test, performed without anaesthesia (< mm 5 in 5 minutes). 
2. Rose bengal score or other ocular dye score (> 4 according to van Bijsterveld´s 
scoring system). 
 
IV.  Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) 
       focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus     
       score > 1, defined as a number of lymphocytic foci (which are adjacent to normal- 
       appearing mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular 
       tissue. 
 
V.  Salivary gland involvement: objective evidence of salivary gland involvement defined by 
a positive result for at least one of the following diagnostic test: 
1. Unstimulated whole salivary flow (< 1.5 ml in 15 minutes). 
2. Parotid sialography showing the presence of diffuse sialectasiasis (punctate, 
caviatary or destructive pattern), without evidence of obstruction in the major 
ducts. 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or 
delayed excretion tracer. 
 
VI. Autoantibodies: presence in the serum of the following autoantibodies:  
      Antibodies to Ro (SSA) or La (SSB) antigens, or both. 
 
For primary SS 
In patients without any potentially associated disease, primary SS may be defined as follows: 
a) The presence of any 4 of the 6 items is indicative of primary SS, as long as either 
item IV (Histopathology) or VI (Serology) is positive. 
b) The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, 
VI). 
c) The classification tree procedure represents a valid alternative method for 
classification, although it should be more properly used in clinical-
epidemiological survey. 
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Exclusion criteria 
a) Past head and neck radiation treatment 
b) Hepatitis C infection 
c) Acquired immunodeficiency disease (AIDS) 
d) Pre-existing lymphoma 
e) Sarcoidois 
f) Graft versus host disease 
g) Use of anticholinergic drugs (since at time shorter than 4-fold the half life of the drug) 
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Errata 
Paper V 
Page 8, lines 5-7, should read: “Amplitudes of the motor responses tended to be lower in the 
group with abnormal F-wave latencies, but these differences did not reach statistical 
significance (Fig. 2B).” 
 
Page 8, lines 12-14, should read: “The mean IENF densities in the leg were significantly 
lower in patients with PSS compared with normative values and as also observed in SLE 
patients.” 
